secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2023-04-03T23:59:59+00:00
Accession:  0000950170-23-011476
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR and Vertex complete rolling BLA submission to FDA for exa-cel for SCD and TDT
--------------------------------------------------------------------------------

- Completed rolling Biologics License Applications for exa-cel for sickle cell disease and transfusion-dependent beta thalassemia.
- Requests Priority Review; if granted, FDA review shortened to 8 months vs 12.
- Supported by Phase 3 data from CLIMB-111, CLIMB-121, and long-term follow-up CLIMB-131.
- EU and UK filings submitted Dec 2022, validated by EMA and MHRA in Jan 2023.
- Exa-cel has RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease designations from FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023011476/0000950170-23-011476-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023011476/crsp-20230331.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-011476

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer